Epidermal growth factor receptor tyrosine kinase inhibitors are widely used in the management of metastatic non-small cell lung cancer. Adverse events, their impact on quality of life and treatment adherence with these oral drugs are discussed.

Lung cancer is the leading cause of death by cancer in Europe, Canada and the US. In the last few years, treatment of metastatic lung cancer has evolved and has become more personalised based on new characterisations of the disease.

READ FULL ARTICLE Curated publisher From Pharmacy Europe